Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
CD8-positive T-lymphocytes
active
dendritic cells
immunotherapy
programmed cell death 1 receptor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
27
10
2020
entrez:
21
11
2020
pubmed:
22
11
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was an extension part of the study. Patients with metastatic melanoma were treated with efti plus the standard dose of pembrolizumab. Blood samples were assayed to determine plasma pharmacokinetic parameters, detect efti antibody formation and determine long-lived CD8 T cell responses and associated pharmacodynamic parameters. Twenty-four patients with melanoma received pembrolizumab and bi-weekly subcutaneous (s.c.) injections of efti at doses 1 mg, 6 mg or 30 mg/injection for up to 6 months (part A) or 30 mg/injection for up 12 months (part B). No dose-limiting toxicities were reported and the main adverse event for efti was injection site reactions. Sustained systemic exposure to the product was obtained in all patients following s.c. injections of 30 mg dose. Treatment induced an increase in activated CD8 and CD4 T cell counts, and in some of the soluble biomarkers, particularly interferon (IFN)-γ, a Th1 signature cytokine. An overall response rate (ORR) of 33% was observed in patients partly with pembrolizumab-refractory of part A and ORR of 50% was observed in patients with PD-1 naïve of part B. Efti was well tolerated in combination with pembrolizumab with encouraging antitumor activity. This warrants further clinical studies of this new combination therapy combining an antigen-presenting cell activator with an immune checkpoint inhibitor.
Sections du résumé
BACKGROUND
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.
METHODS
The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was an extension part of the study. Patients with metastatic melanoma were treated with efti plus the standard dose of pembrolizumab. Blood samples were assayed to determine plasma pharmacokinetic parameters, detect efti antibody formation and determine long-lived CD8 T cell responses and associated pharmacodynamic parameters.
RESULTS
Twenty-four patients with melanoma received pembrolizumab and bi-weekly subcutaneous (s.c.) injections of efti at doses 1 mg, 6 mg or 30 mg/injection for up to 6 months (part A) or 30 mg/injection for up 12 months (part B). No dose-limiting toxicities were reported and the main adverse event for efti was injection site reactions. Sustained systemic exposure to the product was obtained in all patients following s.c. injections of 30 mg dose. Treatment induced an increase in activated CD8 and CD4 T cell counts, and in some of the soluble biomarkers, particularly interferon (IFN)-γ, a Th1 signature cytokine. An overall response rate (ORR) of 33% was observed in patients partly with pembrolizumab-refractory of part A and ORR of 50% was observed in patients with PD-1 naïve of part B.
CONCLUSIONS
Efti was well tolerated in combination with pembrolizumab with encouraging antitumor activity. This warrants further clinical studies of this new combination therapy combining an antigen-presenting cell activator with an immune checkpoint inhibitor.
Identifiants
pubmed: 33219094
pii: jitc-2020-001681
doi: 10.1136/jitc-2020-001681
pmc: PMC7682474
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antigens, CD
0
Antineoplastic Agents, Immunological
0
pembrolizumab
DPT0O3T46P
Lymphocyte Activation Gene 3 Protein
0
soluble LAG-3 protein, human
0
Lag3 protein, human
0
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: CM, CB and FT are employees of Immutep and own shares of the company.
Références
Blood. 2003 Sep 15;102(6):2130-7
pubmed: 12775570
Clin Cancer Res. 2009 Oct 1;15(19):6225-31
pubmed: 19755389
J Immune Based Ther Vaccines. 2007 Mar 29;5:5
pubmed: 17394654
Nature. 1998 Jun 4;393(6684):474-8
pubmed: 9624003
Front Immunol. 2019 Apr 02;10:604
pubmed: 31001249
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Cancer Discov. 2018 Oct;8(10):1250-1257
pubmed: 30154193
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32690667
Cancer Discov. 2018 Oct;8(10):1258-1269
pubmed: 30154192
Tissue Antigens. 2008 Sep;72(3):187-94
pubmed: 18627571
Vaccine. 2007 Jun 11;25(24):4641-50
pubmed: 17493710
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
J Immunol. 2007 Sep 15;179(6):4202-11
pubmed: 17785860
J Transl Med. 2010 Jul 23;8:71
pubmed: 20653948
Lancet Respir Med. 2019 Apr;7(4):347-357
pubmed: 30876831
Cancer Res. 2006 Apr 15;66(8):4450-60
pubmed: 16618772
J Immunol. 2002 Apr 15;168(8):3874-80
pubmed: 11937541